The polycystic ovary syndrome (PCOS) drugs market share is expected to increase by USD 711.14 million from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 5%.

The market research report provides valuable insights into the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by drug class (insulin-sensitizing agents, oral contraceptives, aromatase inhibitors, and other drug classes) and geography (North America, Europe, Asia, and ROW).

The polycystic ovary syndrome (PCOS) drugs market report also offers information on several market vendors, including AbbVie Inc., Bayer AG, Bristol-Myers Squibb Co., Cipla Inc., Ferring Pharmaceuticals AS, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. among others.

AbbVie Inc. - VANIQA: It is used to slow down the growth of unwanted hair on the face and under the chin in women with PCOS. Under the unified segment, the company operates in only one business segment that focuses on the discovery, development, manufacturing, and commercialization of drugs for the treatment of various indications.

What will the Polycystic Ovary Syndrome (PCOS) Drugs Market Size be During the Forecast Period?

Get the Polycystic Ovary Syndrome (PCOS) Drugs Market Size Forecast by Downloading the Report Sample

Parent Market Analysis

Technavio categorizes the global PCOS drugs market as a part of the pharmaceutical market within the overall healthcare industry. Our research report extensively covers external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the polycystic ovary syndrome (PCOS) drugs market during the forecast period.

Polycystic Ovary Syndrome (PCOS) Drugs Market: Key Drivers, Trends, and Challenges

Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Polycystic Ovary Syndrome (PCOS) Drugs Market Driver

• One of the key factors driving growth in the polycystic ovary syndrome (PCOS) drugs market is the increasing prevalence of chronic diseases.
• Although the main cause of PCOS is still undetermined, high levels of male hormones are likely to prevent the ovaries from producing female hormones and making eggs normally.
• Patients with diabetes may have several clinical conditions, including overweight, hypertension, and obesity, which are risk factors for PCOS. PCOS is correlated with type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, depression, and even excessive body hair. It also has serious implications for fertility. Therefore, the rising prevalence of these conditions across the globe is expected to increase the patient pool with a large number of women having PCOS, which, in turn, will drive the growth of the global PCOS drugs market during the forecast period.

Key Polycystic Ovary Syndrome (PCOS) Drugs Market Challenge

• The lack of approved drugs will be a major challenge for the polycystic ovary syndrome (PCOS) drugs market during the forecast period.
• PCOS is a complicated lifelong condition whose pathophysiology and etiology have not yet been understood in their entirety.
• As of yet, no medication has been approved by the US Food and Drug Administration (FDA) solely for the treatment of PCOS.
• The process of balancing efficacy and safety in PCOS drugs taken by women of any age, who have the condition, is very difficult. However, the symptoms and presentation of PCOS are often amenable to several approved agents, such as oral contraceptives for the indication of acne and clomiphene citrate for the indication of induction of ovulation.
• Drugs that lower the androgen levels are another common treatment used for PCOS, although they are not officially approved by the US FDA for the treatment of PCOS. Therefore, due to the lack of branded drugs approved for this indication, the market is witnessing limited growth. 

This polycystic ovary syndrome (PCOS) drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Polycystic Ovary Syndrome (PCOS) Drugs Market Value Chain Analysis

Our In-house experts produce extensive information on the value chain and parent market of the polycystic ovary syndrome (PCOS) drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The Value Chain information provides an end-to-end understanding of product insight and profit and also optimization and evaluation of business strategies. The players across the value chain include selective data and analysis from entire research findings as per the scope of the report.

Which are the Key Regions for Polycystic Ovary Syndrome (PCOS) Drugs Market?

Get a glance at the market share of various regions by Requesting a PDF Sample now!

35% of the market’s growth will originate from North America during the forecast period. The US is the key market for polycystic ovary syndrome (PCOS) drugs in North America. Market growth in this region will be faster than the growth of the market in the European regions.

The presence of well-established pharmaceutical giants in the region and huge investments from governments for patient assistance and R&D activities will result in the region accounting for a high share of the global PCOS drugs market during the forecast period. This will facilitate the polycystic ovary syndrome (PCOS) drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What is the Fastest-Growing Drug Class Segment in the Polycystic Ovary Syndrome (PCOS) Drugs Market?

To gain insights on the market contribution of various segments Request a PDF Sample

The polycystic ovary syndrome (PCOS) drugs market share growth by the insulin sensitizing agents segment will be significant during the forecast period. Insulin-sensitizing agents such as metformin are used for women with PCOS, oligo/amenorrhea, and subfertility since the administration of these agents improves the chances of clinical pregnancy and ovulation. Thus, the benefits of insulin-sensitizing agents in PCOS patients are expected to drive the sales of PCOS drugs during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the polycystic ovary syndrome (PCOS) drugs market size and actionable market insights on the post-COVID-19 impact on each segment.

Request PDF sample

What are the Key Data Covered in this Polycystic Ovary Syndrome (PCOS) Drugs Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive polycystic ovary syndrome (PCOS) drugs market growth during the next five years
• Precise estimation of the polycystic ovary syndrome (PCOS) drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behaviour
• The growth of the polycystic ovary syndrome (PCOS) drugs market industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive analysis of factors that will challenge the growth of polycystic ovary syndrome (PCOS) drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch